211 related articles for article (PubMed ID: 31980928)
1. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis.
Riffel P; Schwaab J; Lutz C; Naumann N; Metzgeroth G; Fabarius A; Schoenberg SO; Hofmann WK; Valent P; Reiter A; Jawhar M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):945-951. PubMed ID: 31980928
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.
Rossini M; Zanotti R; Bonadonna P; Artuso A; Caruso B; Schena D; Vecchiato D; Bonifacio M; Viapiana O; Gatti D; Senna G; Riccio A; Passalacqua G; Pizzolo G; Adami S
Bone; 2011 Oct; 49(4):880-5. PubMed ID: 21782049
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis.
Riffel P; Jawhar M; Gawlik K; Schwaab J; Michaely HJ; Metzgeroth G; Hofmann WK; Schoenberg SO; Reiter A
Ann Hematol; 2019 Dec; 98(12):2693-2701. PubMed ID: 31686155
[TBL] [Abstract][Full Text] [Related]
4. Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF
Taylor F; Akin C; Lamoureux RE; Padilla B; Green T; Boral AL; Mazar I; Mar B; Shields AL; Siebenhaar F
Orphanet J Rare Dis; 2021 Oct; 16(1):414. PubMed ID: 34627355
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis.
Artuso A; Caimmi C; Tripi G; Viapiana O; Bonifacio M; Idolazzi L; Gavioli I; Gatti D; Zanotti R; Rossini M
Calcif Tissue Int; 2017 Jan; 100(1):40-46. PubMed ID: 27743017
[TBL] [Abstract][Full Text] [Related]
6. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis.
Seitz S; Barvencik F; Koehne T; Priemel M; Pogoda P; Semler J; Minne H; Pfeiffer M; Zustin J; Püschel K; Eulenburg C; Schinke T; Amling M
Osteoporos Int; 2013 Aug; 24(8):2325-34. PubMed ID: 23436077
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.
Lübke J; Schwaab J; Christen D; Elberink HO; Span B; Niedoszytko M; Gorska A; Lange M; Gleixner KV; Hadzijusufovic E; Solomianyi O; Angelova-Fischer I; Zanotti R; Bonifacio M; Bonadonna P; Shoumariyeh K; von Bubnoff N; Müller S; Perkins C; Elena C; Malcovati L; Hagglund H; Mattsson M; Parente R; Varkonyi J; Fortina AB; Caroppo F; Zink A; Brockow K; Breynaert C; Bullens D; Yavuz AS; Doubek M; Sabato V; Schug T; Niederwieser D; Hartmann K; Triggiani M; Gotlib J; Hermine O; Arock M; Kluin-Nelemans HC; Panse J; Sperr WR; Valent P; Reiter A; Jawhar M
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):581-590.e5. PubMed ID: 36403897
[TBL] [Abstract][Full Text] [Related]
8. Frequency and prognostic impact of
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Henriques A; Viñas E; Prieto C; Sánchez-Muñoz L; Caldas C; Mayado A; Matito A; Dasilva-Freire N; Orfao A; García-Montero AC
Blood; 2019 Aug; 134(5):456-468. PubMed ID: 31151985
[TBL] [Abstract][Full Text] [Related]
9. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
10. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density in patients with systemic mastocytosis: correlations with clinical and histopathological features.
Meyer HJ; Pönisch W; Monecke A; Gundermann P; Surov A
Clin Exp Rheumatol; 2021; 39(1):52-57. PubMed ID: 32301423
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis.
van der Veer E; van der Goot W; de Monchy JG; Kluin-Nelemans HC; van Doormaal JJ
Allergy; 2012 Mar; 67(3):431-8. PubMed ID: 22229787
[TBL] [Abstract][Full Text] [Related]
13. Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis.
Schwaab J; Cabral do O Hartmann N; Naumann N; Jawhar M; Weiß C; Metzgeroth G; Schmid A; Lübke J; Reiter L; Fabarius A; Cross NCP; Sotlar K; Valent P; Kluin-Nelemans HC; Hofmann WK; Horny HP; Panse J; Reiter A
J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3121-3127.e1. PubMed ID: 32422371
[TBL] [Abstract][Full Text] [Related]
14. Fracture Risk Reduction by Bisphosphonates in Mastocytosis?
Onnes MC; van Doormaal JJ; van der Veer E; Versluijs JB; Arends S; Oude Elberink HNG
J Allergy Clin Immunol Pract; 2020; 8(10):3557-3564. PubMed ID: 32673882
[TBL] [Abstract][Full Text] [Related]
15. Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis.
Riffel J; Lübke J; Naumann N; Kreil S; Metzgeroth G; Fabarius A; Sotlar K; Horny HP; Jawhar M; Overhoff D; Schoenberg S; Hofmann WK; Henzler T; Schwaab J; Reiter A; Riffel P
Sci Rep; 2022 Aug; 12(1):14228. PubMed ID: 35987779
[TBL] [Abstract][Full Text] [Related]
16. Avapritinib for Systemic Mastocytosis.
Bose P; Verstovsek S
Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
[TBL] [Abstract][Full Text] [Related]
17. Adverse Prognostic Impact of the
Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
Lim KH; Tefferi A; Lasho TL; Finke C; Patnaik M; Butterfield JH; McClure RF; Li CY; Pardanani A
Blood; 2009 Jun; 113(23):5727-36. PubMed ID: 19363219
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.
Gehlen M; Schmidt N; Pfeifer M; Balasingam S; Schwarz-Eywill M; Maier A; Werner M; Siggelkow H
Calcif Tissue Int; 2021 Dec; 109(6):685-695. PubMed ID: 34223956
[TBL] [Abstract][Full Text] [Related]
20. MR-based trabecular bone microstructure is not altered in subjects with indolent systemic mastocytosis.
Baum T; Karampinos DC; Brockow K; Seifert-Klauss V; Jungmann PM; Biedermann T; Rummeny EJ; Bauer JS; Müller D
Clin Imaging; 2015; 39(5):886-9. PubMed ID: 25542754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
